Literature DB >> 18468560

Recent progress in antiretrovirals--lessons from resistance.

Catherine S Adamson1, Eric O Freed.   

Abstract

Recent failures in efforts to develop an effective vaccine against HIV-1 infection have emphasized the importance of antiretroviral therapy in treating HIV-1-infected patients. Thus far, inhibitors of two viral enzymes, reverse transcriptase and protease, have had a profoundly positive impact on the survival of HIV-1-infected patients. However, new inhibitors that act at diverse steps in the viral replication cycle are urgently needed because of the development of resistance to currently available antiretrovirals. This review summarizes recent progress in antiretroviral drug discovery and development by specifically focusing on novel inhibitors of three phases of replication: viral entry, integration of the viral DNA into the host cell genome and virus particle maturation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18468560      PMCID: PMC2581412          DOI: 10.1016/j.drudis.2008.02.003

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  87 in total

1.  HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use.

Authors:  Alexandra Trkola; Shawn E Kuhmann; Julie M Strizki; Elizabeth Maxwell; Tom Ketas; Tom Morgan; Pavel Pugach; Serena Xu; Lisa Wojcik; Jayaram Tagat; Anandan Palani; Sherry Shapiro; John W Clader; Stuart McCombie; Gregory R Reyes; Bahige M Baroudy; John P Moore
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-08       Impact factor: 11.205

Review 2.  HIV entry inhibitors targeting gp41: from polypeptides to small-molecule compounds.

Authors:  Shuwen Liu; Shuguang Wu; Shibo Jiang
Journal:  Curr Pharm Des       Date:  2007       Impact factor: 3.116

3.  Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells.

Authors:  D J Hazuda; P Felock; M Witmer; A Wolfe; K Stillmock; J A Grobler; A Espeseth; L Gabryelski; W Schleif; C Blau; M D Miller
Journal:  Science       Date:  2000-01-28       Impact factor: 47.728

4.  Anti-human immunodeficiency virus activity of YK-FH312 (a betulinic acid derivative), a novel compound blocking viral maturation.

Authors:  T Kanamoto; Y Kashiwada; K Kanbara; K Gotoh; M Yoshimori; T Goto; K Sano; H Nakashima
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

5.  Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design.

Authors:  Y Goldgur; R Craigie; G H Cohen; T Fujiwara; T Yoshinaga; T Fujishita; H Sugimoto; T Endo; H Murai; D R Davies
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-09       Impact factor: 11.205

Review 6.  Chemokine antagonists as therapeutics: focus on HIV-1.

Authors:  Athe M N Tsibris; Daniel R Kuritzkes
Journal:  Annu Rev Med       Date:  2007       Impact factor: 13.739

7.  Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals.

Authors:  Martin Markowitz; Javier O Morales-Ramirez; Bach-Yen Nguyen; Colin M Kovacs; Roy T Steigbigel; David A Cooper; Ralph Liporace; Robert Schwartz; Robin Isaacs; Lucinda R Gilde; Larissa Wenning; Jing Zhao; Hedy Teppler
Journal:  J Acquir Immune Defic Syndr       Date:  2006-12-15       Impact factor: 3.731

8.  HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase.

Authors:  A S Espeseth; P Felock; A Wolfe; M Witmer; J Grobler; N Anthony; M Egbertson; J Y Melamed; S Young; T Hamill; J L Cole; D J Hazuda
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-10       Impact factor: 11.205

Review 9.  Dissecting HIV fusion: identifying novel targets for entry inhibitors.

Authors:  C Finnegan; R Blumenthal
Journal:  Infect Disord Drug Targets       Date:  2006-12

10.  PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing.

Authors:  F Li; R Goila-Gaur; K Salzwedel; N R Kilgore; M Reddick; C Matallana; A Castillo; D Zoumplis; D E Martin; J M Orenstein; G P Allaway; E O Freed; C T Wild
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-22       Impact factor: 11.205

View more
  17 in total

1.  EASY-HIT: HIV full-replication technology for broad discovery of multiple classes of HIV inhibitors.

Authors:  Stephan Kremb; Markus Helfer; Werner Heller; Dieter Hoffmann; Horst Wolff; Andrea Kleinschmidt; Sabine Cepok; Bernhard Hemmer; Jörg Durner; Ruth Brack-Werner
Journal:  Antimicrob Agents Chemother       Date:  2010-09-27       Impact factor: 5.191

2.  Anti-HIV-1 therapeutics: from FDA-approved drugs to hypothetical future targets.

Authors:  Catherine S Adamson; Eric O Freed
Journal:  Mol Interv       Date:  2009-04

Review 3.  Novel approaches to inhibiting HIV-1 replication.

Authors:  Catherine S Adamson; Eric O Freed
Journal:  Antiviral Res       Date:  2009-09-24       Impact factor: 5.970

Review 4.  HIV type 1 Gag as a target for antiviral therapy.

Authors:  Abdul A Waheed; Eric O Freed
Journal:  AIDS Res Hum Retroviruses       Date:  2011-09-21       Impact factor: 2.205

Review 5.  New insights into HIV assembly and trafficking.

Authors:  Muthukumar Balasubramaniam; Eric O Freed
Journal:  Physiology (Bethesda)       Date:  2011-08

Review 6.  HIV-1 gag: an emerging target for antiretroviral therapy.

Authors:  Philip R Tedbury; Eric O Freed
Journal:  Curr Top Microbiol Immunol       Date:  2015       Impact factor: 4.291

7.  Recombinant rabbit single-chain antibodies bind to the catalytic and C-terminal domains of HIV-1 integrase protein and strongly inhibit HIV-1 replication.

Authors:  Frederico Aires da Silva; Min Li; Sylvie Rato; Sara Maia; Rui Malhó; Kylie Warren; David Harrich; Robert Craigie; Carlos Barbas; Joao Goncalves
Journal:  Biotechnol Appl Biochem       Date:  2012-10-10       Impact factor: 2.431

8.  Computer-based design of novel HIV-1 entry inhibitors: neomycin conjugated to arginine peptides at two specific sites.

Authors:  Alexander Berchanski; Aviva Lapidot
Journal:  J Mol Model       Date:  2008-12-05       Impact factor: 1.810

9.  Impact of human immunodeficiency virus type 1 resistance to protease inhibitors on evolution of resistance to the maturation inhibitor bevirimat (PA-457).

Authors:  Catherine S Adamson; Kayoko Waki; Sherimay D Ablan; Karl Salzwedel; Eric O Freed
Journal:  J Virol       Date:  2009-03-11       Impact factor: 5.103

Review 10.  Virus maturation as a new HIV-1 therapeutic target.

Authors:  Catherine S Adamson; Karl Salzwedel; Eric O Freed
Journal:  Expert Opin Ther Targets       Date:  2009-08       Impact factor: 6.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.